8-K
filed September 13, 2023, 7:59 PM ET
ticker CSBR
CIK 0000771856
earnings
confidence high
sentiment negative
materiality 0.75
Champions Oncology Q1 revenue $12.6M, down 9%; operating loss widens to $2.6M
CHAMPIONS ONCOLOGY, INC.
2024-Q1 EPS reported
-$0.19
revenue$12,561,000
- Revenue $12.6M vs $13.7M YoY (-8.6%); gross margin 38.8% vs 48.7%.
- Operating loss $2.6M vs loss of $284K; adjusted EBITDA loss $1.7M vs positive $450K.
- Cash $5.0M, no debt; net cash used in ops $4.0M for the quarter.
- CEO cites biotech downturn; bookings improving, expects revenue growth in H2.
- Drug discovery subsidiary Corellia AI progressing; company seeking capital to accelerate programs.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.85
CHAMPIONS ONCOLOGY, INC. reported financial results for first quarter of fiscal 2024 ended July 31, 2023.
- Period
- first quarter of fiscal 2024 ended July 31, 2023
- Result
- reported results
Exact text from the filing
Total revenue for the first quarter of fiscal 2024 was $12.6 million compared to $13.7 million for the same period last year, a decrease of 8.6%.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.85
CHAMPIONS ONCOLOGY, INC. reported financial results for first quarter of fiscal 2024 ended July 31, 2023.
- Period
- first quarter of fiscal 2024 ended July 31, 2023
- Result
- reported results
Exact text from the filing
For the first quarter of fiscal 2024, Champions reported a loss from operations of $2.6 million , including $423,000 in stock-based compensation and $445,000 in depreciation and amortization expenses, compared to a loss from operations of $284,000 , inclusive of $206,000 in stock-based compensation and $528,000 in depreciation and amortization expenses, in the first quarter of fiscal 2023.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.85
CHAMPIONS ONCOLOGY, INC. reported financial results for first quarter of fiscal 2024 ended July 31, 2023.
- Period
- first quarter of fiscal 2024 ended July 31, 2023
- Result
- reported results
Exact text from the filing
Excluding stock-based compensation, depreciation and amortization expenses, Champions reported an adjusted EBITDA loss of $1.7 million for the first quarter of fiscal 2024 compared to adjusted EBITDA of $450,000 in the first quarter of fiscal 2023.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.